View Item 

Show simple item record

Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostateâ specific antigen screening in 2012
dc.contributor.authorButler, Santino S.
dc.contributor.authorMuralidhar, Vinayak
dc.contributor.authorZhao, Shuang G.
dc.contributor.authorSanford, Nina N.
dc.contributor.authorFranco, Idalid
dc.contributor.authorFullerton, Zoe H.
dc.contributor.authorChavez, Janice
dc.contributor.authorD’amico, Anthony V.
dc.contributor.authorFeng, Felix Y.
dc.contributor.authorRebbeck, Timothy R.
dc.contributor.authorNguyen, Paul L.
dc.contributor.authorMahal, Brandon A.
dc.date.accessioned2020-02-05T15:08:03Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-02-05T15:08:03Z
dc.date.issued2020-02-15
dc.identifier.citationButler, Santino S.; Muralidhar, Vinayak; Zhao, Shuang G.; Sanford, Nina N.; Franco, Idalid; Fullerton, Zoe H.; Chavez, Janice; D’amico, Anthony V. ; Feng, Felix Y.; Rebbeck, Timothy R.; Nguyen, Paul L.; Mahal, Brandon A. (2020). "Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostateâ specific antigen screening in 2012." Cancer (4): 717-724.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/153721
dc.publisherWiley Periodicals, Inc.
dc.publisherNational Comprehensive Cancer Network, Inc
dc.subject.otherprostate cancer
dc.subject.otherPSA screening
dc.subject.otherprostatic neoplasms
dc.subject.otherincidence
dc.titleProstate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostateâ specific antigen screening in 2012
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/153721/1/cncr32604.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/153721/2/cncr32604_am.pdf
dc.identifier.doi10.1002/cncr.32604
dc.identifier.sourceCancer
dc.identifier.citedreferenceNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Prostate Cancer. Version 2.2018. National Comprehensive Cancer Network, Inc. Published March 8, 2018. Accessed July 1, 2018. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
dc.identifier.citedreferenceDraisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostateâ specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003; 95: 868 â 878.
dc.identifier.citedreferenceHu JC, Nguyen P, Mao J, et al. Increase in prostate cancer distant metastases at diagnosis in the United States. JAMA Oncol. 2017; 3: 705 â 707. doi: 10.1001/jamaoncol.2016.5465
dc.identifier.citedreferenceJemal A, Ma J, Siegel R, Fedewa S, Brawley O, Ward EM. Prostate cancer incidence rates 2 years after the US Preventive Services Task Force recommendations against screening. JAMA Oncol. 2016; 2: 1657 â 1660. doi: 10.1001/jamaoncol.2016.2667
dc.identifier.citedreferenceJemal A, Fedewa SA, Ma J, et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA. 2015; 314: 2054 â 2061. doi: 10.1001/jama.2015.14905
dc.identifier.citedreferenceTiwari RC, Clegg LX, Zou Z. Efficient interval estimation for ageâ adjusted cancer rates. Stat Methods Med Res. 2006; 15: 547 â 569. doi: 10.1177/0962280206070621
dc.identifier.citedreferenceNational Cancer Institute Surveillance, Epidemiology, and End Results Program. PSA values and SEER data. Accessed July 1, 2018. https://seer.cancer.gov/data/psaâ values.html.
dc.identifier.citedreferenceNational Cancer Institute Surveillance, Epidemiology, and End Results Program. SEER*Stat Databases: November 2017 submission. Accessed July 1, 2018. https://seer.cancer.gov/dataâ software/documentation/seerstat/nov2018/.
dc.identifier.citedreferencePotosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995; 273: 548 â 552.
dc.identifier.citedreferenceUS Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008; 149: 185 â 191.
dc.identifier.citedreferenceMoyer VA, et al. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 157: 120 â 134.
dc.identifier.citedreferenceAndriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostateâ cancer screening trial. N Engl J Med. 2009; 360: 1310 â 1319.
dc.identifier.citedreferenceSchroder FH, Hugosson J, Roobol MJ, et al. Screening and prostateâ cancer mortality in a randomized European study. N Engl J Med. 2009; 360: 1320 â 1328.
dc.identifier.citedreferencePenson DF. The pendulum of prostate cancer screening. JAMA. 2015; 314: 2031 â 2033.
dc.identifier.citedreferenceSchroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of followâ up. Lancet. 2014; 384: 2027 â 2035.
dc.identifier.citedreferenceGrossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018; 319: 1901 â 1913.
dc.identifier.citedreferenceTornblom M, Eriksson H, Franzen S, et al. Lead time associated with screening for prostate cancer. Int J Cancer. 2004; 108: 122 â 129. doi: 10.1002/ijc.11554
dc.identifier.citedreferenceHugosson J, Aus G, Becker C, et al. Would prostate cancer detected by screening with prostateâ specific antigen develop into clinical cancer if left undiagnosed? A comparison of two populationâ based studies in Sweden. BJU Int. 2000; 85: 1078 â 1084.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr32604.pdf
Size:
594.6KB
Format:
PDF
View/Open
Name:
cncr32604_am.pdf
Size:
252.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.